ADDRESSING THE TECHNICAL AND CLINICAL CHALLENGES OF NEXT-GENERATION CELL THERAPIES AND REGENERATIVE MEDICINES
Optimized reagents and cell lines to streamline cell therapy protocols
Scalable technologies, safer methods, and custom solutions designed to help scientists and process development professionals.
Human growth factors and cytokines from human expression models, differentiated stem cell lines, and customized services.
Accelerate your cell-based research and pre-IND-enabling activities.
OPTIMIZE YOUR CELL-BASED WORKFLOWS
When faced with in-house technical challenges and budget constraints, we returned to first principles to design optimized cellular engineering technologies that are scalable, efficient, and cost-effective.
Need a custom solution for a challenging cell manufacturing application?
Contact us today to learn how our innovative technological platforms and products can help solve your cell engineering needs.
Technologies
As bench scientists first and commercial solution providers second, we leverage decades of technical problem-solving in cellular and tissue engineering to develop best-in-class reprogramming methods and critical, high-value consumables for use in cell-based workflows.
Our technologies aim to advance cell-based therapy development by lowering the technical performance hurdles of programming and differentiation protocols and increasing the clinical safety profiles of developing next-generation medicines.
Our proprietary humanized yeast and immortalized stem cell lines express proteins with native (human) post-translational modifications (PTM), subunit assemblies, and secondary folding. Unlike proteins expressed in non-human E. coli and CHO-based systems, which lack complete glycosylated peptide sequences, our proteins most closely resemble proteins in the human body. We also employ the latest tagging technologies to maximize the bioavailability of our growth factors.
Discover how our fully human, cost-effective growth factors and cytokines can streamline your cell differentiation protocols.
Our hypoimmunogenic stem cells do not express canonical human leukocyte antigen (HLA) molecules, such as major histocompatibility complex (MHC) Class I and Class II. Our proprietary methods create cells that eliminate the burdens of HLA type matching in allogeneic therapeutic design and cell transplantation applications. These hypoimmune cells can be used as target cells for downstream reprogramming and terminal cell type differentiation.
Our cells are developed using our proprietary virus-free (non-integrating) and oncogene-free methods, presenting the lowest downstream clinical risk profile compared to other programming methods.
Contact us to learn how our hypoimmune cells can accelerate your allogeneic research efforts and therapeutic development.
Utilizing non-integrating, episomal DNA with our proprietary mix of transcription factors and small molecules, our patented method to program induced pluripotent stem cells (iPSCs) results in a scalable cell line with the lowest downstream clinical risk profile.
Our methods eliminate the use of c-Myc, l-Myc, and Lin28, which have been linked to downstream neoplastic risks, and our resulting cells are suitable for adherent and suspension-based applications.
Our intellectual property is unencumbered and readily available for research, co-development, and licensing opportunities.